Compare Summit Therapeutics Inc (SMMT) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Synopsys, Inc. — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.98B), while Synopsys, Inc. trades at $397.42 (market cap $75.36B). The key difference: Synopsys, Inc. is far larger — about 5.4× Summit Therapeutics Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| SMMT | SNPS | |
|---|---|---|
Market Cap | $13.98B | $75.36B |
Sector | Health | Technology |
52-Week High | $26.38 | $534.56 |
52-Week Low | $12.43 | $372.33 |
Enterprise Value | $13.31B | $82.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, while P/B stands at 22.19. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancer, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.18 suggesting 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish with 61% buy ratings, but the stock remains speculative due to its pre-revenue status and dependence on a single drug candidate.
Synopsys (SNPS) trades at $392.03, down 0.46% on the day, with a bearish technical signal from moving averages but strong fundamental performance including three consecutive quarterly EPS beats. Revenue reached $7.05B in 2025 with an 11.43% net income margin, though valuation ratios like a P/E of 68.42 appear elevated. Recent news highlights its critical role in AI chip design and integration benefits from the Ansys acquisition.
The outlook is supported by Wall Street's bullish consensus with a $541.88 price target, but risks include high valuation sensitivity, competitive pressures in semiconductor software, and macroeconomic headwinds. Earnings growth and execution on raised 2026 guidance are key catalysts for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
